Literature DB >> 25153131

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society.

D J Portman, M L S Gass.   

Abstract

BACKGROUND: In 2012, the Board of Directors of the International Society for the Study of Women's Sexual Health (ISSWSH) and the Board of Trustees of The North American Menopause Society (NAMS) acknowledged the need to review current terminology associated with genitourinary tract symptoms related to menopause.
METHODS: The two societies cosponsored a terminology consensus conference, which was held in May 2013. RESULTS AND
CONCLUSION: Members of the consensus conference agreed that the term genitourinary syndrome of menopause (GSM) is a medically more accurate, all-encompassing, and publicly acceptable term than vulvovaginal atrophy. GSM is defined as a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra and bladder. The syndrome may include but is not limited to genital symptoms of dryness, burning, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired function; and urinary symptoms of urgency, dysuria and recurrent urinary tract infections. Women may present with some or all of the signs and symptoms, which must be bothersome and should not be better accounted for by another diagnosis. The term was presented and discussed at the annual meeting of each society. The respective Boards of NAMS and ISSWSH formally endorsed the new terminology - genitourinary syndrome of menopause (GSM) - in 2014.

Entities:  

Keywords:  ATROPHIC VAGINITIS; GENITOURINARY SYNDROME OF MENOPAUSE; MENOPAUSE; URINARY URGENCY; VULVOVAGINAL ATROPHY; WOMEN’S SEXUAL HEALTH

Mesh:

Year:  2014        PMID: 25153131     DOI: 10.3109/13697137.2014.946279

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  21 in total

Review 1.  Perimenopause: From Research to Practice.

Authors:  Nanette Santoro
Journal:  J Womens Health (Larchmt)       Date:  2015-12-10       Impact factor: 2.681

Review 2.  The etiology and management of recurrent urinary tract infections in postmenopausal women.

Authors:  Carrie Jung; Linda Brubaker
Journal:  Climacteric       Date:  2019-01-09       Impact factor: 3.005

Review 3.  Should Dehydroepiandrosterone Be Administered to Women?

Authors:  Margaret E Wierman; Katja Kiseljak-Vassiliades
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

4.  Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment.

Authors:  A R Mothes; M Runnebaum; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-27       Impact factor: 4.553

5.  Efficacy of N-acetylcysteine, D-mannose and Morinda citrifolia to Treat Recurrent Cystitis in Breast Cancer Survivals.

Authors:  Debora Marchiori; Pier Paolo Zanello
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

6.  Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause.

Authors:  M Gambacciani; M Levancini; M Cervigni
Journal:  Climacteric       Date:  2015-10       Impact factor: 3.005

7.  The efficacy of erbium-doped yttrium aluminum garnet (Er:YAG) laser in the treatment of decreased sexual sensation: a randomized, placebo-controlled trial.

Authors:  Angkana Sathaworawong; Woraphong Manuskiatti; Chayawat Phatihattakorn; Chanida Ungaksornpairote; Janice Natasha Ng
Journal:  Lasers Med Sci       Date:  2021-04-01       Impact factor: 3.161

8.  Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial.

Authors:  Jumara Martins; Ana Francisca Vaz; Regina Celia Grion; Lúcia Costa-Paiva; Luiz Francisco Baccaro
Journal:  BMC Cancer       Date:  2021-06-10       Impact factor: 4.430

9.  Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.

Authors:  R E Nappi; S Palacios; N Panay; M Particco; M L Krychman
Journal:  Climacteric       Date:  2015-11-19       Impact factor: 3.005

Review 10.  Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?

Authors:  D Edwards; N Panay
Journal:  Climacteric       Date:  2015-12-26       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.